Performance of placebo tablets
GRANFILLER-D GNF-D211 / GNF-D215 are compatible with “100N tablet hardness” and “20 sec oral disintegration time” in 250mg φ8mm.
GRANFILLER-D can realize excellent disintegration even under high compression force.
Basic Performance ( 250mg, Φ8mm, Flat Beveled Edge )
|Compression Force ( kN )||4||6||8||4||6||8|
|Tablet Hardness ( N )||50||80||110||52||83||108|
|Disintegration Time [Pharmacopoeia] ( s )||12||15||21||11||15||18|
|Oral Disintegration Time [in vivo] ( s )||13||14||22||11||11||14|
|Oral Disintegration [in vitro] ( s )||12||16||25||9||12||18|
|Friability ( % )||0.30||0.12||0.06||0.23||0.05||0.05|
- Components of ODT :
- GNF-D211/GNF-D215 ( 99.5% ) + Mg Stearate ( 0.5% )
- Tablet Hardness :
- Measured by electronic hardness teaser ( Avg. n=10 )
- Disintegration Time :
- Measured by JP general test method ( Avg. n=6 )
- Oral Disintegration Time :
- ( in vivo ) 3 Times at a time measured by 3 adults ( Avg. n=9 )
( in vivo ) Measured by Tricorptester ( Okada Seiko Co., Ltd. Tokyo, Japan )
- Friability :
- Measured by JP general test method
- Tableting Condition :
- Rotary-Press, 6 stations, 20 rpm, 250mg, Φ8mm, Flat Beveled Edge
Contribution of unique Granulation to compaction property
Applying unique wet granulation method, GRANFILLER-D improves compaction property compared to simple mixture of individual ingredients.
- Components of ODT：
- GNF-D211( 99.5% ) ＋Mg Stearate ( 0.5% )
- Tablet Hardness ：
- Measured by electronic hardness tester ( Ave. of n＝10 )
- Disintegration Time ：
- Measured by JP general test method ( Ave. of n＝6 )
- Tableting Conditions ：
- Hand-press tableting, 250mg, φ8mm, Flat Face Bevel Edge
Example application – High dose API
GRANFILLER-D makes high-dose formulation possible.
1. High-Dose Ethenzamide ( ETZ ) ODT
|API Content [ % ]||0||30||50||70|
|Compression Force ( kN )||6||7||9||5||7||5|
|Tablet Hardness ( N )||80||69||94||57||91||80|
|Disintegration Time ( s )||15||16||19||15||18||18|
|Oral Disintegration Time ( s )||16||16||21||16||25||-|
|Friability ( s )||0.12||0.18||0.13||0.31||0.15||0.30|
Daicel pays special attention to ensure that the information included in this website is updated and accurate.
However, Daicel does not guarantee nor does it accept any responsibility for the appropriateness and accuracy of the information in this website.
Additionally, the information in this website may be changed or suspended, and the operations thereof ceased, without prior notice.
Regardless of the reason, Daicel does not assume responsibility for any damage arising from changes in the information in this website.
( 06/2017 )